E213: The Diagnostic Room: We have AI initiatives, but do we have a strategy? The quickest self-test

Many pharma and life science organisations have been investing in AI for years: pilots across commercial, medical, regulatory, and R&D, innovation labs, steering committees, vendor spend, and genuine effort from smart teams. And yet the same story keeps showing up in boardrooms: ROI is unclear, adoption is patchy, and leaders struggle to explain how all the AI activity connects to strategic goals.

In this solo episode, Dr Andree Bates steps into “The Diagnostic Room” to explain why this happens, and why it’s usually not a technology, talent, or speed issue. It’s a diagnosis issue: organisations often haven’t identified what is actually constraining value, so they end up executing hard on the wrong problem.

Dr Andree shares a real example from a mid-sized pharma company that believed its AI programme was failing due to lack of velocity. On the surface, it was a reasonable hypothesis. But a focused diagnostic revealed three hidden structural blockers: unclear decision rights for scaling pilots into production, fragmented data ownership preventing access to the best datasets, and incentive misalignment where the people expected to adopt AI tools were not rewarded for the behaviours those tools required.

She then clarifies what a diagnostic is and is not. A diagnostic is not a strategy, roadmap, vendor shortlist, financial model, or implementation plan. Instead, it provides evidence-based clarity: what’s broken, how you compare to peers, what’s at stake, and what questions have been opened that cannot responsibly be answered in ten days. That clarity creates a shared language for leadership, replacing vague frustration with a precise problem statement.

The organisations pulling ahead are not simply those with the biggest budgets, but those willing to find what’s actually broken before trying to fix it.

Topics Covered

Why AI initiatives can grow without creating measurable ROI

The gap between pilots and a true AI strategy

Misdiagnosis: executing brilliantly on the wrong problem

What a diagnostic sprint is (and what it is not)

Three hidden blockers

Why working groups can’t fix structural AI constraints

What a full strategic AI blueprint includes

Why many AI business cases are untested projections

How to improve board confidence with evidence, governance, and measurement

Why diagnostics create speed by creating shared clarity

Eularis helps pharma and biotech leaders turn AI activity into board-defensible strategy and measurable commercial outcomes.

If your organisation has plenty of AI in motion but very little that moves the commercial needle in a way the board can see, start with our 10-Day AI Diagnostic Sprint. It’s a focused diagnostic that surfaces what’s actually broken and what’s blocking results, before you invest in a larger strategy effort.

The Sprint diagnoses the problem. The AI Strategic Blueprint that follows is where we build the board-defensible strategy and plan.

Details at eularis.com.

About the Podcast

AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.

This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.

If this episode described your situation, send me a LinkedIn DM starting with ‘SENSECHECK’ and two things: the question you’re trying to answer internally, and what’s currently in flight. I’ll reply with what I’d need to see to turn that activity into a defensible plan, and the next step.

Dr. Andree Bates LinkedIn | Facebook | X